Data Insights

Ponatinib hydrochloride by Takeda Pharmaceutical for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Ponatinib hydrochloride is under clinical development by Takeda Pharmaceutical and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Ponatinib Hydrochloride in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

TAK-861 by Takeda Pharmaceutical for Type 1 Narcolepsy (Narcolepsy with Cataplexy): Likelihood of Approval

TAK-861 is under clinical development by Takeda Pharmaceutical and currently in Phase III for Type 1 Narcolepsy (Narcolepsy with Cataplexy)....

Likelihood of Approval and Phase Transition Success Rate Model - TAK-861 in Type 1 Narcolepsy (Narcolepsy with Cataplexy)

Data Insights

Mobocertinib by Takeda Pharmaceutical for Metastatic Biliary Tract Cancer: Likelihood of Approval

Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Biliary Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mobocertinib in Metastatic Biliary Tract Cancer

Data Insights

Lanadelumab by Takeda Pharmaceutical for Angioedema: Likelihood of Approval

Lanadelumab is under clinical development by Takeda Pharmaceutical and currently in Phase III for Angioedema. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Lanadelumab in Angioedema

Data Insights

Fruquintinib by Takeda Pharmaceutical for Angiosarcoma: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Angiosarcoma

Data Insights

Fruquintinib by Takeda Pharmaceutical for Metastatic Pancreatic Cancer: Likelihood of Approval

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Fruquintinib in Metastatic Pancreatic Cancer

Data Insights

C1 esterase inhibitor (human) by Takeda Pharmaceutical for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

C1 esterase inhibitor (human) is under clinical development by Takeda Pharmaceutical and currently in Phase II for Acquired (Autoimmune) Hemolytic...

Likelihood of Approval and Phase Transition Success Rate Model - C1 Esterase Inhibitor (Human) in Acquired (Autoimmune) Hemolytic Anemia

Data Insights

TAK-500 by Takeda Pharmaceutical for Pancreatic Cancer: Likelihood of Approval

TAK-500 is under clinical development by Takeda Pharmaceutical and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - TAK-500 in Pancreatic Cancer

Data Insights

Mezagitamab by Takeda Pharmaceutical for IgA Nephropathy (Berger's Disease): Likelihood of Approval

Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase I for IgA Nephropathy (Berger's Disease). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Mezagitamab in IgA Nephropathy (Berger's Disease)

Data Insights

Soticlestat by Takeda Pharmaceutical for Lennox-Gastaut Syndrome: Likelihood of Approval

Soticlestat is under clinical development by Takeda Pharmaceutical and currently in Phase III for Lennox-Gastaut Syndrome. According to GlobalData, Phase...

Data Insights

Subasumstat by Takeda Pharmaceutical for Solid Tumor: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Subasumstat in Solid Tumor

Data Insights

Sitocabnagene loxiveluecel by Takeda Pharmaceutical for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Sitocabnagene loxiveluecel is under clinical development by Takeda Pharmaceutical and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Sitocabnagene Loxiveluecel in Primary Mediastinal B-Cell Lymphoma

Data Insights

Sitocabnagene loxiveluecel by Takeda Pharmaceutical for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Sitocabnagene loxiveluecel is under clinical development by Takeda Pharmaceutical and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Sitocabnagene Loxiveluecel in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

Sitocabnagene loxiveluecel by Takeda Pharmaceutical for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Sitocabnagene loxiveluecel is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL)....

Likelihood of Approval and Phase Transition Success Rate Model - Sitocabnagene Loxiveluecel in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

Sitocabnagene loxiveluecel by Takeda Pharmaceutical for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

Sitocabnagene loxiveluecel is under clinical development by Takeda Pharmaceutical and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sitocabnagene Loxiveluecel in B-Cell Non-Hodgkin Lymphoma

Data Insights

Sitocabnagene loxiveluecel by Takeda Pharmaceutical for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Sitocabnagene loxiveluecel is under clinical development by Takeda Pharmaceutical and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Sitocabnagene Loxiveluecel in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Mezagitamab by Takeda Pharmaceutical for Myasthenia Gravis: Likelihood of Approval

Mezagitamab is under clinical development by Takeda Pharmaceutical and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Mezagitamab in Myasthenia Gravis

Data Insights

Sitocabnagene loxiveluecel by Takeda Pharmaceutical for Follicular Lymphoma: Likelihood of Approval

Sitocabnagene loxiveluecel is under clinical development by Takeda Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sitocabnagene Loxiveluecel in Follicular Lymphoma

Data Insights

Sitocabnagene loxiveluecel by Takeda Pharmaceutical for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Sitocabnagene loxiveluecel is under clinical development by Takeda Pharmaceutical and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...

Data Insights

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...